Barok M - Search Results

1

HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer.

Attalla SS, Boucher J, Proud H, Taifour T, Zuo D, Sanguin-Gendreau V, Ling C, Johnson G, Li V, Luo RB, Kuasne H, Papavasiliou V, Walsh LA, Barok M, Joensuu H, Park M, Roux PP, Muller WJ. Attalla SS, et al. Among authors: barok m. Cancer Immunol Res. 2023 Sep 1;11(9):1184-1202. doi: 10.1158/2326-6066.CIR-22-0140. Cancer Immunol Res. 2023. PMID: 37311021

2

Trastuzumab emtansine: mechanisms of action and drug resistance.

Barok M, Joensuu H, Isola J. Barok M, et al. Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621. Breast Cancer Res. 2014. PMID: 24887180 Free PMC article. Review.

3

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.

Barok M, Puhka M, Vereb G, Szollosi J, Isola J, Joensuu H. Barok M, et al. BMC Cancer. 2018 May 2;18(1):504. doi: 10.1186/s12885-018-4418-2. BMC Cancer. 2018. PMID: 29720111 Free PMC article.

4

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, Joensuu H, Barok M. Le Joncour V, et al. Among authors: barok m. Mol Cancer Ther. 2019 Oct;18(10):1721-1730. doi: 10.1158/1535-7163.MCT-19-0207. Epub 2019 Jul 10. Mol Cancer Ther. 2019. PMID: 31292166

5

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.

Barok M, Le Joncour V, Martins A, Isola J, Salmikangas M, Laakkonen P, Joensuu H. Barok M, et al. Cancer Lett. 2020 Mar 31;473:156-163. doi: 10.1016/j.canlet.2019.12.037. Epub 2020 Jan 2. Cancer Lett. 2020. PMID: 31904483

6

Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.

Barok M, Puhka M, Yazdi N, Joensuu H. Barok M, et al. J Extracell Vesicles. 2021 Feb;10(4):e12070. doi: 10.1002/jev2.12070. Epub 2021 Feb 13. J Extracell Vesicles. 2021. PMID: 33613875 Free PMC article. Review.

7

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.

Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, Joensuu H, Barok M. Pourjamal N, et al. Among authors: barok m. Clin Exp Metastasis. 2024 Apr;41(2):91-102. doi: 10.1007/s10585-024-10278-2. Epub 2024 Feb 17. Clin Exp Metastasis. 2024. PMID: 38367127 Free PMC article.

8

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Barok M, Tanner M, Köninki K, Isola J. Barok M, et al. Cancer Lett. 2011 Jul 28;306(2):171-9. doi: 10.1016/j.canlet.2011.03.002. Epub 2011 Apr 1. Cancer Lett. 2011. PMID: 21458915

9

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.

Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, Hemmilä P, Ilvesaro J, Isola J. Köninki K, et al. Among authors: barok m. Cancer Lett. 2010 Aug 28;294(2):211-9. doi: 10.1016/j.canlet.2010.02.002. Epub 2010 Mar 2. Cancer Lett. 2010. PMID: 20193978

10

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Barok M, Tanner M, Köninki K, Isola J. Barok M, et al. Breast Cancer Res. 2011 Apr 21;13(2):R46. doi: 10.1186/bcr2868. Breast Cancer Res. 2011. PMID: 21510863 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters